These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 27214873

  • 1. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D.
    Dalton Trans; 2016 Aug 16; 45(33):12983-91. PubMed ID: 27214873
    [Abstract] [Full Text] [Related]

  • 2. The Platin-X series: activation, targeting, and delivery.
    Basu U, Banik B, Wen R, Pathak RK, Dhar S.
    Dalton Trans; 2016 Aug 16; 45(33):12992-3004. PubMed ID: 27493131
    [Abstract] [Full Text] [Related]

  • 3. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
    Najjar A, Rajabi N, Karaman R.
    Curr Pharm Des; 2017 Aug 16; 23(16):2366-2376. PubMed ID: 28155621
    [Abstract] [Full Text] [Related]

  • 4. Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Gibson D.
    J Inorg Biochem; 2019 Feb 16; 191():77-84. PubMed ID: 30471522
    [Abstract] [Full Text] [Related]

  • 5. Platinum(IV) Prodrugs.
    Venkatesh V, Sadler PJ.
    Met Ions Life Sci; 2018 Feb 05; 18():. PubMed ID: 29394022
    [Abstract] [Full Text] [Related]

  • 6. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF, Wong DY, Jothibasu R, Ang WH.
    Curr Top Med Chem; 2011 Feb 05; 11(21):2602-12. PubMed ID: 22039869
    [Abstract] [Full Text] [Related]

  • 7. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A, González-Cantó A, Escribano E, Barrabés S, Artigas G, Moreno V, Marchán V.
    Dalton Trans; 2015 Jan 07; 44(1):202-12. PubMed ID: 25369773
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P, Montagner D, Ang WH.
    ChemMedChem; 2018 Jun 20; 13(12):1210-1217. PubMed ID: 29637702
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 13. The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.
    Montaña AM, Batalla C.
    Curr Med Chem; 2009 Sep 05; 16(18):2235-60. PubMed ID: 19519389
    [Abstract] [Full Text] [Related]

  • 14. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
    Gibson D.
    ChemMedChem; 2021 Jul 20; 16(14):2188-2191. PubMed ID: 33928760
    [Abstract] [Full Text] [Related]

  • 15. Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one.
    Gabano E, Ravera M, Osella D.
    Dalton Trans; 2014 Jul 14; 43(26):9813-20. PubMed ID: 24874896
    [Abstract] [Full Text] [Related]

  • 16. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z, Deng Z, Zhu G.
    Dalton Trans; 2019 Feb 19; 48(8):2536-2544. PubMed ID: 30633263
    [Abstract] [Full Text] [Related]

  • 17. Advances in platinum chemotherapeutics.
    Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR.
    Chemistry; 2010 Jun 25; 16(24):7064-77. PubMed ID: 20533453
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.